50 Years of EU Pharma Legislation

Multicenter, open-label, 156-week extension trial finds that Qulipta (atogepant) reduced migraine days and acute medication use in patients with chronic or episodic migraine.

In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.

In the fifth and final part of this video interview with ACT editor Andy Studna, Stephen Pyke, chief clinical data and digital officer, Parexel, highlights the importance of human oversight when using artificial intelligence to aid in decision making.

In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.

The current clinical development model is shifting toward a generative AI-augmented proactive approach supported by real-world data for real time evidence.

A full summary of the acute adverse effects of psilocybin in the treatment of depression and anxiety is vital for health care providers to provide effective patient counseling.